Polymeric plerixafor: Effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection

Yan Wang, Jing Li, David Oupicky

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Methods: Polymeric Plerixafor (PAMD) was synthesized from Plerixafor (AMD3100) and grafted with different amounts of PEG (2 kDa). CXCR4 antagonism of the synthesized polymers was determined using receptor redistribution assay. Inhibition of cancer cell invasion by the polyplexes of the synthesized polymers was assessed using Boyden-chamber method. Transfection activity of DNA polyplexes formed with the synthesized polymers was evaluated in U2OS osteosarcoma and B16F10 melanoma cells.

Results: Our results demonstrate that modification of PAMD with PEG decreased toxicity of the polymers, while preserving their CXCR4 antagonism. Polyplexes prepared with PEG-PAMD inhibited invasion of cancer cells to an extent similar to the commercial CXCR4 antagonist Plerixafor. Negative effect of PEG on transfection activity of PEG-PAMD polyplexes could be overcome by using polyplexes formulated with a mixture of PAMD and PEG-PAMD.

Conclusion: Modification of PAMD with PEG is a viable strategy to preserve the desirable CXCR4 antagonism and ability to inhibit cancer cell invasion of PAMD, while improving safety and colloidal stability of the PAMD polyplexes.

Purpose: To determine the effect of PEG modification on pharmacologic and gene delivery properties of polymeric CXCR4 antagonist based on Plerixafor.

Original languageEnglish (US)
Pages (from-to)3538-3548
Number of pages11
JournalPharmaceutical Research
Volume31
Issue number12
DOIs
StatePublished - Dec 2014

Fingerprint

Polyethylene glycols
Transfection
Cells
Polymers
DNA
Neoplasms
Osteosarcoma
Melanoma
JM 3100
Safety
Toxicity
Assays
Genes

Keywords

  • CXCR4 antagonists
  • gene delivery
  • polyplexes
  • transfection

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Polymeric plerixafor : Effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection. / Wang, Yan; Li, Jing; Oupicky, David.

In: Pharmaceutical Research, Vol. 31, No. 12, 12.2014, p. 3538-3548.

Research output: Contribution to journalArticle

@article{1495797bb85c41718d12f5ee5fffb58d,
title = "Polymeric plerixafor: Effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection",
abstract = "Methods: Polymeric Plerixafor (PAMD) was synthesized from Plerixafor (AMD3100) and grafted with different amounts of PEG (2 kDa). CXCR4 antagonism of the synthesized polymers was determined using receptor redistribution assay. Inhibition of cancer cell invasion by the polyplexes of the synthesized polymers was assessed using Boyden-chamber method. Transfection activity of DNA polyplexes formed with the synthesized polymers was evaluated in U2OS osteosarcoma and B16F10 melanoma cells.Results: Our results demonstrate that modification of PAMD with PEG decreased toxicity of the polymers, while preserving their CXCR4 antagonism. Polyplexes prepared with PEG-PAMD inhibited invasion of cancer cells to an extent similar to the commercial CXCR4 antagonist Plerixafor. Negative effect of PEG on transfection activity of PEG-PAMD polyplexes could be overcome by using polyplexes formulated with a mixture of PAMD and PEG-PAMD.Conclusion: Modification of PAMD with PEG is a viable strategy to preserve the desirable CXCR4 antagonism and ability to inhibit cancer cell invasion of PAMD, while improving safety and colloidal stability of the PAMD polyplexes.Purpose: To determine the effect of PEG modification on pharmacologic and gene delivery properties of polymeric CXCR4 antagonist based on Plerixafor.",
keywords = "CXCR4 antagonists, gene delivery, polyplexes, transfection",
author = "Yan Wang and Jing Li and David Oupicky",
year = "2014",
month = "12",
doi = "10.1007/s11095-014-1440-1",
language = "English (US)",
volume = "31",
pages = "3538--3548",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Polymeric plerixafor

T2 - Effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection

AU - Wang, Yan

AU - Li, Jing

AU - Oupicky, David

PY - 2014/12

Y1 - 2014/12

N2 - Methods: Polymeric Plerixafor (PAMD) was synthesized from Plerixafor (AMD3100) and grafted with different amounts of PEG (2 kDa). CXCR4 antagonism of the synthesized polymers was determined using receptor redistribution assay. Inhibition of cancer cell invasion by the polyplexes of the synthesized polymers was assessed using Boyden-chamber method. Transfection activity of DNA polyplexes formed with the synthesized polymers was evaluated in U2OS osteosarcoma and B16F10 melanoma cells.Results: Our results demonstrate that modification of PAMD with PEG decreased toxicity of the polymers, while preserving their CXCR4 antagonism. Polyplexes prepared with PEG-PAMD inhibited invasion of cancer cells to an extent similar to the commercial CXCR4 antagonist Plerixafor. Negative effect of PEG on transfection activity of PEG-PAMD polyplexes could be overcome by using polyplexes formulated with a mixture of PAMD and PEG-PAMD.Conclusion: Modification of PAMD with PEG is a viable strategy to preserve the desirable CXCR4 antagonism and ability to inhibit cancer cell invasion of PAMD, while improving safety and colloidal stability of the PAMD polyplexes.Purpose: To determine the effect of PEG modification on pharmacologic and gene delivery properties of polymeric CXCR4 antagonist based on Plerixafor.

AB - Methods: Polymeric Plerixafor (PAMD) was synthesized from Plerixafor (AMD3100) and grafted with different amounts of PEG (2 kDa). CXCR4 antagonism of the synthesized polymers was determined using receptor redistribution assay. Inhibition of cancer cell invasion by the polyplexes of the synthesized polymers was assessed using Boyden-chamber method. Transfection activity of DNA polyplexes formed with the synthesized polymers was evaluated in U2OS osteosarcoma and B16F10 melanoma cells.Results: Our results demonstrate that modification of PAMD with PEG decreased toxicity of the polymers, while preserving their CXCR4 antagonism. Polyplexes prepared with PEG-PAMD inhibited invasion of cancer cells to an extent similar to the commercial CXCR4 antagonist Plerixafor. Negative effect of PEG on transfection activity of PEG-PAMD polyplexes could be overcome by using polyplexes formulated with a mixture of PAMD and PEG-PAMD.Conclusion: Modification of PAMD with PEG is a viable strategy to preserve the desirable CXCR4 antagonism and ability to inhibit cancer cell invasion of PAMD, while improving safety and colloidal stability of the PAMD polyplexes.Purpose: To determine the effect of PEG modification on pharmacologic and gene delivery properties of polymeric CXCR4 antagonist based on Plerixafor.

KW - CXCR4 antagonists

KW - gene delivery

KW - polyplexes

KW - transfection

UR - http://www.scopus.com/inward/record.url?scp=84928367663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928367663&partnerID=8YFLogxK

U2 - 10.1007/s11095-014-1440-1

DO - 10.1007/s11095-014-1440-1

M3 - Article

C2 - 24942536

AN - SCOPUS:84928367663

VL - 31

SP - 3538

EP - 3548

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 12

ER -